Altimmune Analyst Price Targets

Wall Street analyst price targets and consensus rating for Altimmune (ALT).

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

3S.Buy

7Buy

3Hold

Consensus RatingBuy# Analysts13Avg. Consensus PT$17Upside to Avg. PT+729.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 23, 2026	Evercore ISI Group	Liisa Bayko	PT Cut	Outperform	$18→$17
Jun 22, 2026	Leerink Partners	Thomas Smith	Initiate	Outperform	$10
May 18, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Cut	Buy	$25→$20
May 14, 2026	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$14→$11
Mar 16, 2026	HC Wainwright & Co.	Patrick R. Trucchio	PT Raise	Buy	$12→$25
Mar 6, 2026	B. Riley Securities	William Woods	PT Cut	Buy	$18→$13
Nov 7, 2025	Citizens	Jonathan Wolleben	PT Cut	Market Outperform	$15→$14
Oct 20, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$12
Oct 10, 2025	HC Wainwright & Co.	Patrick R. Trucchio	Maintained	Buy	$12
Aug 13, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$12
Aug 13, 2025	UBS	Eliana Merle	PT Cut	Buy	$26→$24
Aug 13, 2025	B. Riley Securities	Mayank Mamtani	PT Cut	Buy	$20→$18
Jul 10, 2025	JMP Securities	Jonathan Wolleben	PT Cut	Market Outperform	$25→$15
Jun 27, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$12
Apr 3, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$12
Apr 2, 2025	Citizens Capital Markets	Jonathan Wolleben	Maintained	Market Outperform	$25
Mar 18, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$12
Mar 14, 2025	Citizens Capital Markets	Jonathan Wolleben	Maintained	Market Outperform	$25
Mar 3, 2025	HC Wainwright & Co.	Patrick Trucchio	Maintained	Buy	$12
Feb 28, 2025	William Blair	Andy Hsieh	Initiate	Market Perform	—

Analyst Ratings News

PRO
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17

Evercore ISI Group analyst Liisa Bayko maintains Altimmune (NASDAQ:ALT) with a Outperform and lowers the price target from $18 to $17.

Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10

Leerink Partners analyst Thomas Smith initiates coverage on Altimmune (NASDAQ:ALT) with a Outperform rating and announces Price Target of $10.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $25 to $20.

Benzinga Newsdesk

PRO
Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11

Citizens analyst Jonathan Wolleben maintains Altimmune (NASDAQ:ALT) with a Market Outperform and lowers the price target from $14 to $11.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25

HC Wainwright & Co. analyst Patrick R. Trucchio maintains Altimmune (NASDAQ:ALT) with a Buy and raises the price target from $12 to $25.

Benzinga Newsdesk

PRO
B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13

B. Riley Securities analyst William Woods maintains Altimmune (NASDAQ:ALT) with a Buy and lowers the price target from $18 to $13.

Benzinga Newsdesk

Altimmune Inc

Altimmune Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17

PRO
Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10

PRO
HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20

PRO
Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11

PRO
HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25

PRO
B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13

People Also Watch

People Also Watch

Altimmune Inc

Altimmune Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROEvercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17

PROLeerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10

PROHC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20

PROCitizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11

PROHC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25

PROB. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13

People Also Watch

People Also Watch

PRO
Evercore ISI Group Maintains Outperform on Altimmune, Lowers Price Target to $17

PRO
Leerink Partners Initiates Coverage On Altimmune with Outperform Rating, Announces Price Target of $10

PRO
HC Wainwright & Co. Maintains Buy on Altimmune, Lowers Price Target to $20

PRO
Citizens Maintains Market Outperform on Altimmune, Lowers Price Target to $11

PRO
HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $25

PRO
B. Riley Securities Maintains Buy on Altimmune, Lowers Price Target to $13